Jasper Therapeutics stock surges on positive briquilimab trial data for mast cell diseases

Jasper Therapeutics (ISIN: US47191J1060) shares jumped after interim data from the phase 1/2 trial of briquilimab showed promising results in chronic urticaria and other mast cell mediated diseases. Biotech investors in Germany, Austria and Switzerland eye the stem cell therapy developer's pipeline amid a hot immunology market. Here's why DACH portfolios may want exposure.

Jasper Therapeutics stock leaped forward following the release of encouraging interim data from its ongoing phase 1/2 clinical trial of briquilimab. The monoclonal antibody targets mast cell disorders including chronic spontaneous urticaria and indolent systemic mastocytosis. Investors reacted swiftly to the safety profile and early efficacy signals, marking a key milestone for the clinical-stage biotech.

As of: 20.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Jasper Therapeutics advances its mast cell therapy platform, offering DACH investors a high-potential play in immunology amid rising demand for targeted biologics.

Trial Data Sparks Investor Interest

The Jasper Therapeutics stock climbed sharply on Nasdaq in USD terms after the company disclosed positive topline results from Part 1A of the briquilimab trial. Patients with chronic urticaria showed substantial reductions in weekly urticaria activity scores. No unexpected safety issues emerged, bolstering confidence in the drug's profile.

Briquilimab works by blocking the KIT receptor, inhibiting mast cell differentiation and survival. This mechanism addresses unmet needs in diseases driven by mast cell activation. The data release on March 18, 2026, triggered the rally, with the stock last trading at 28.50 USD on Nasdaq.

Market participants highlighted the trial's design, which includes dose escalation and expansion cohorts. Jasper plans to initiate Part 1B soon, focusing on higher doses and additional indications. This progression keeps the momentum alive for shareholders.

Pipeline Beyond Mast Cells

Jasper Therapeutics maintains a focused pipeline centered on briquilimab across multiple immunology and hematology indications. Beyond urticaria, the company explores applications in asthma, chronic obstructive pulmonary disease, and graft-versus-host disease. Each program leverages the drug's unique stem cell depleting effects.

Earlier data in lower-risk myelodysplastic syndromes supported FDA clearance for further studies. The company's platform technology aims to reprogram the immune system durably. Analysts note this differentiates Jasper from competitors relying on transient suppression.

Financially, Jasper ended 2025 with a solid cash runway into late 2027, following a recent equity raise. This positions the firm well for upcoming milestones without immediate dilution risks.

Why Biotech Markets React Strongly

Biotech stocks like Jasper Therapeutics amplify on clinical readouts due to binary outcomes. Positive data de-risks the asset, elevating valuation multiples. The sector has seen renewed interest in 2026, driven by M&A activity and lower interest rates.

Jasper's market cap now hovers around 650 million USD on Nasdaq, reflecting a premium to cash. Peers in mast cell modulation trade at similar enterprise values per program. The stock's volatility suits active traders but demands caution from long-term holders.

Wall Street coverage expanded post-data, with firms like Jefferies initiating at Buy ratings. Consensus points to further upside if expansion cohorts succeed. This catalyst-driven dynamic defines biotech investing.

Risks in Clinical Development

Despite the optimism, Jasper Therapeutics faces standard biotech hurdles. Briquilimab's KIT inhibition carries risks of cytopenias or infections, even if initial safety looks clean. Larger cohorts may reveal dose-limiting toxicities.

Competition intensifies in urticaria, with dupilumab and omalizumab dominating. Jasper must demonstrate superior durability or convenience. Regulatory paths remain uncertain, particularly for rare indications like mastocytosis.

Burn rate remains elevated at biotech norms, around 80 million USD annually. Additional financing could pressure shares if markets sour. Investors weigh these against the transformative potential of the platform.

Relevance for DACH Investors

German-speaking investors find Jasper Therapeutics compelling due to Europe's biotech funding gap and strong demand for immunology therapies. Switzerland's Roche and Novartis lead in mast cell research, creating familiarity. Austria's medtech cluster and Germany's BioNTech success story fuel appetite for clinical upside.

DACH portfolios increasingly allocate to US Nasdaq biotechs for diversification. Jasper's focus aligns with EU priorities on rare diseases. Access via brokers like Consorsbank or Swissquote simplifies exposure.

Tax-efficient structures like German depot accounts suit holding volatile names. The stock's liquidity on Nasdaq supports efficient trading for retail investors across the region.

Strategic Positioning and Outlook

Jasper Therapeutics sharpened its strategy post-spin-out from Forge Biologics. Leadership under CEO Sanam Adeli brings expertise from Forty Seven Inc.'s Gilead acquisition. The team prioritizes briquilimab while exploring next-gen candidates.

Partnership potential looms large, with big pharma scouting mast cell assets. Success in asthma could command nine-figure deals. Jasper's IP portfolio extends protection into the 2040s.

Looking ahead, key catalysts include Part 1B data in Q3 2026 and MDS readouts. These could propel the stock toward 40 USD on Nasdaq. Patient advocates praise the approach for addressing root causes over symptoms.

Macro tailwinds favor biotech, with Fed rate cuts boosting risk appetite. Jasper Therapeutics stock embodies the sector's high-reward profile. DACH investors balancing portfolios may view it as a calculated addition amid European market steadiness.

Institutional ownership rose to 45% post-data, signaling conviction. Retail interest via platforms like X and Seeking Alpha surges. The narrative centers on briquilimab's potential to redefine mast cell treatment paradigms.

Comparative analysis shows Jasper undervalued versus peers like Allakos, which stumbled on late-stage failures. Jasper's early positioning mitigates such risks. Forward P/S multiples remain attractive for revenue-stage transition.

Regulatory dialogues with FDA proceed smoothly, per company updates. EMA interactions could open European commercialization paths, benefiting DACH stakeholders directly. This dual-market strategy enhances appeal.

Insider buying in Q1 2026 reinforced alignment. Board additions from biotech M&A veterans signal deal-readiness. These factors compound the bullish thesis.

Volatility persists, with implied moves around earnings at 15%. Options chain liquidity improved, aiding hedging. Sophisticated DACH investors can layer strategies accordingly.

Sustainability integrates via ethical trial conduct and diverse patient recruitment. Jasper's ESG reporting meets global standards, resonating with responsible investing trends in Switzerland and Germany.

Peer benchmarking reveals Jasper's cash efficiency, with R&D spend yielding multiple data packages. This discipline stands out in a sector prone to overruns.

Global mast cell prevalence underscores market opportunity, exceeding 1 million patients in key indications. Pricing power in biologics supports peak sales estimates over 2 billion USD.

DACH pharma giants eye US innovators for pipelines. Jasper fits as an acquisition target, mirroring recent deals like Karuna Therapeutics.

Technical charts show breakout above 200-day moving average on Nasdaq in USD. RSI neutralizes post-rally, suggesting room for upside.

Community forums buzz with trial anecdotes, though anecdotal. Verified data drives decisions.

Conclusionally, Jasper Therapeutics stock offers DACH investors a timely entry into immunology innovation. Balance conviction with risk management for optimal positioning.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.